Chemistry:Rosonabant

From HandWiki
Short description: Chemical compound
Rosonabant
Rosonabant.svg
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H21Cl3N4O
Molar mass451.78 g·mol−1
3D model (JSmol)

Rosonabant (INN; E-6776) is a drug acting as a CB1 receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity.[1][2] Development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued in November 2008,[when?] due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly acting agents.[3][4][5]

See also

References

  1. "Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis". Expert Opinion on Emerging Drugs 14 (1): 43–65. March 2009. doi:10.1517/14728210902736568. PMID 19249987. 
  2. "Preclinical Developments in Antiobesity Drugs". Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. 2007. p. 325. ISBN 978-0-12-370633-1. https://books.google.com/books?id=YO3BUp3nicMC&pg=PA325. Retrieved 12 May 2012. 
  3. "Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders". British Journal of Clinical Pharmacology 68 (6): 861–874. December 2009. doi:10.1111/j.1365-2125.2009.03549.x. PMID 20002080. 
  4. "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry 9 (6): 482–503. 2009. doi:10.2174/156802609788897844. PMID 19689362. http://www.benthamdirect.org/pages/content.php?CTMC/2009/00000009/00000006/0003R.SGM. 
  5. "The psychiatric side-effects of rimonabant". Revista Brasileira de Psiquiatria 31 (2): 145–153. June 2009. doi:10.1590/S1516-44462009000200012. PMID 19578688.